Alpha Cognition Enrolls First Patient in ZUNVEYL Phase 4 Study

Alpha Cognition enrolled the first patient in RESOLVE, a Phase 4 post-marketing study evaluating ZUNVEYL in mild to moderate Alzheimer's disease. The study will collect safety and tolerability data and explore changes in neuropsychiatric symptoms in an outpatient setting. Approximately 150 patients will be enrolled across multiple clinical sites.